Moderna Inc. (NASDAQ:MRNA) finished Wednesday with an addition of $10.37 to close at $321.50, an upside of 3.33 percent. An average of 11,402,440 shares of common stock have been traded in the last five days. There was a gain of $19.08 in the past week. The last 20 days have seen an average of 14,431,900 shares traded, while the 50-day average volume stands at 17,555,465.
MRNA stock has decreased by -24.83% in the last month. The company shares reached their 1-month lowest point of $293.58 on 10/07/21. With the stock rallying to its 52-week high on 08/10/21, shares of the company touched a low of $65.49 and a high of $497.49 in 52 weeks. In spite of this, the price is down -35.38% from the 52-week high.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
3 days have passed since Moderna Inc. (MRNA) last reported insider trading activity. Andres Juan, who is See remarks, most recently acquired $15,000 shares at $300.00 per share on Oct 11. In this transaction, the insider spent $4,500,000. See remarks, Andres Juan, disposed of 5,000 shares at a price of $310.44 on Oct 08. The insider now owns more than $1,552,200 worth of shares. Prior to that, Chief Executive Officer Bancel Stephane went on to Sale 10,000 shares at $295.00 each on Oct 07. An amount of $2,950,000 was transacted.
Moderna Inc. (MRNA) has a trailing price-to-earnings (P/E) ratio of 40.13, which compares with the 34.65 for the broader industry and 32.30 for the sector. In the last five years, Moderna Inc.’s PE ratio has ranged between 187.57 and 27.67. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 18.76, the price-to-book (PB) ratio at 19.27, and the price-to-cash flow ratio at 14.50.
The quick ratio of Moderna Inc. for the three months ended June 29 was 1.20, and the current ratio was 1.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.05 and a total debt to equity ratio of 0.07 for the quarter ending June 29. Moderna Inc.’s EBITDA margin for the year ending June 29 is -91.10%, while its operating margin for the same period stands at 54.40%. Its gross profit as reported stood at $795.46 million compared to revenue of $803.39 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Moderna Inc.’s return on assets was 34.20%, compared to -22.0% over the last five years. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Moderna Inc. had $2.39 billion in cash. The analyst consensus anticipated Moderna Inc.’s latest quarter earnings to come in at $5.95 per share, but it turned out to be $6.46, a 8.60% surprise. For the quarter, EBITDA amounted to $3.14 billion. Shareholders own equity worth $403.65 million.
From a technical analysis perspective, let’s take a brief look at Moderna Inc. (MRNA) price momentum. RSI 9-day as of the close on 13 October was 35.81%, suggesting the stock is Neutral, with historical volatility in this time frame at 81.00%.
As of today, MRNA’s price is $310.40 +6.31% or $19.08 from its 5-day moving average. MRNA is currently trading -26.00% lower than its 20-day SMA and +99.13% higher than its 100-day SMA. However, the stock’s current price level is -16.82% below the SMA50 and +188.60% above the SMA200.
The stochastic %K and %D were 11.69% and 9.22%, respectively, and the average true range (ATR) was 22.63. With the 14-day stochastic at 17.45% and the average true range at 23.70, the RSI (14) stands at 37.64%. The stock has reached -4.47 on the 9-day MACD Oscillator while the 14-day reading was at -33.17.
Piper Sandler downgraded Moderna Inc. (NASDAQ: MRNA) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a an Overweight.The consensus rating for Moderna Inc. (MRNA) among analysts is Hold. According to current brokerage recommendations, 3 brokerage firms advise that investors sell MRNA, while 7 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is MRNA’s price target for the next 12 months?
Analysts predict a range of price targets between $85.00 and $485.00, with a median target of $453.00. Taking a look at these predictions, the average price target given by analysts for Moderna Inc. (MRNA) stock is $351.40.